Market Alert: ASX200 at Critical Support – Reversal or Further Fall?
Recce Pharmaceuticals (ASX: RCE) has announced a capital raise of up to AU$15.8 million to support its advancing clinical pipeline. The raise includes an AU$5.0 million placement to an Australian-based private investor and an AU$10.8 million pro-rata non-renounceable entitlement offer to existing shareholders, both at an offer price of AU$0.28 per share. These funds will primarily be used to initiate and progress Phase III clinical trials for topical treatments of Diabetic Foot Infections (DFI) in Indonesia and Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Australia.
The placement is expected to settle on 16 April 2025, and the entitlement offer will be open from 22 April to 5 May 2025. Directors intend to participate, signaling strong internal support. With a strengthened cash position and expected R&D rebates and advances, Recce is strategically positioned to generate revenue by 2026 and drive value through clinical development milestones.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 16, 2025
Apr 15, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
